ArriVent BioPharma, Inc. (AVBP)

In the past six months, ArriVent BioPharma's stock price has declined by approximately 10.58%, and over the last year, it has decreased by 38.39%. In June 2025, ArriVent announced positive interim data from its Phase 1b FURTHER trial for firmonertinib in EGFR PACC mutant NSCLC. In July 2025, the company completed a public offering, raising $81.1 million. In August 2025, ArriVent BioPharma reported its second-quarter 2025 financial results, indicating a wider net loss than anticipated. In September 2025, ArriVent appointed Brent S. Rice as Chief Commercial Officer and presented the final analysis of firmonertinib monotherapy data from the global Phase 1b study in EGFR PACC mutant NSCLC at the 2025 World Conference on Lung Cancer. In October 2025, ArriVent provided an update on its ongoing pivotal Phase 3 clinical study (ALPACCA) for firmonertinib as a first-line treatment for NSCLC with EGFR PACC uncommon mutations.

Given that ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, the demand for its products and services does not exhibit typical seasonality. The need for cancer therapies is generally constant and driven by disease prevalence and medical necessity rather than seasonal patterns. Demand seasonality is not a relevant factor for ArriVent BioPharma at its current stage of development.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing innovative cancer therapies, particularly for unmet medical needs. The company operates in the Healthcare sector, specifically in Biotechnology & Medical Research and Pharmaceuticals. ArriVent specializes in precision oncology, developing targeted therapies and combination treatments for various cancer types. Its major product candidates include firmonertinib, a tyrosine kinase inhibitor being evaluated in clinical trials for non-small cell lung cancer with EGFR mutations, ARR-217, an antibody-drug conjugate in development for gastrointestinal cancers, and ARR-002, a therapeutic candidate for solid tumors. ArriVent BioPharma was founded in 2021 as a spin-out from Roche's oncology research division.

ArriVent BioPharma, Inc. is headquartered in Newtown Square, Pennsylvania, United States. The company's mission involves accelerating the global development of innovative biopharmaceutical therapeutics and globalizing biopharma innovations from around the world. It also engages in strategic collaborations with international partners such as Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd.

In the past year, ArriVent BioPharma's brand reputation has been positively influenced by its clinical development progress, particularly the encouraging interim data from its Phase 1b FURTHER trial for firmonertinib in EGFR PACC mutant NSCLC. The company's ongoing advancement of its pipeline and strategic collaborations also contribute to a positive perception within the biopharmaceutical community. There is no readily available information indicating any significant negative events or controversies that have adversely affected ArriVent BioPharma's reputation in the past year.

ArriVent BioPharma is predominantly owned by institutional shareholders, who hold approximately 82.89% of the stock, while insiders own about 25.90%, and retail investors hold a smaller percentage. Major institutional owners include Hillhouse Capital Advisors, Ltd., Infinitum Asset Management, LLC, Suvretta Capital Management, LLC, Orbimed Advisors LLC, Fmr LLC, Octagon Capital Advisors LP, BlackRock, Inc., Novo Holdings A/S, and Sofinnova Investments, Inc. Hillhouse Investment Management Ltd is the largest individual shareholder, owning 4.48 million shares, representing 11.05% of the company.